ClinicalTrials.gg
RecruitingNCT06781034GADO-ICHUpdated Jul 1, 2026

Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

An observational study in Cerebral Hemorrhage and Acute Lobar Haematoma, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
128
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Cerebral Hemorrhage with a site in France — 11 open to participants now, 11 under way, 2 of them phase 3. Cerebral Hemorrhage · France.

Planned enrollment
7th of 11
128 · median 455
Started
2025
with 1 other
Observational
11 of 24
7 open now
Primary completion
2026-12
later than 2 of 10 live
Registered
18th of 24
by date
Lead sponsor
1 of 24
Centre Hospitalier Universitaire de Nīmes

Among the 24 studies in Cerebral Hemorrhage with a site in France, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2025, is one of 11 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 18th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

11 of the 24 studies in Cerebral Hemorrhage with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Cerebral Hemorrhage with a site in France, or all of them as a file.
02

Study summary

Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment.

Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis.

An equivalent marker has also been described in gadolinium-enhanced MRI.

By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.

03

Conditions studied

  • Cerebral Hemorrhage
  • Acute Lobar Haematoma

Browse trials for

Keywords

  • Cerebral haemorrhage
  • MRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with acute cerebral hematoma from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy; who underwent a follow-up cerebral CT scan in the event of worsening or for follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;
  • Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.

Exclusion criteria

Exclusion Criteria:

  • Patient refusing to participate
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
128 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients with acute lobar and deep haematoma

    None, pure observational study

    Other: None, pure observational study

Interventions

  • OtherNone, pure observational study

    None, pure observational study

06

What researchers measure

Primary outcomes

  1. Presence of spot sign on gadolinium MRI

    Presence of spot sign on gadolinium MRI (Yes/No)

    Time frame: baseline

  2. Morphologic description of gadolinium MRI spot sign

    morphological (shape, location within the hematoma) description of spot signs on brain MRI

    Time frame: baseline

  3. Quantitative description of gadolinium MRI spot sign

    Quantitative (number and categorial) description of spot signs on brain MRI

    Time frame: baseline

Secondary outcomes

  1. association of spot sign with hematoma expansion on follow-up CT

    association of spot sign with hematoma expansion on follow-up CT(Yes/No)

    Time frame: Baseline

  2. Association with the underlaying pathology

    Association with the underlaying pathology as identified by the authors (Yes/No)

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Feb 3, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06781034
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Feb 3, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 1, 2026

Study contacts

Teodora PARVU
Contact
teodora.parvu@chu-nimes.fr
04.66.68.32.61
Anissa MEGZARI
study director · Centre Hospitalier Universitaire de Nīmes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion